Relevant bibliographies by topics / Subcutaneous heparin injection

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Subcutaneous heparin injection'

Author: Grafiati
Published: 4 June 2021
Last updated: 26 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Subcutaneous heparin injection.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Subcutaneous heparin injection"

1

Baer, CL, WM Bennett, DA Folwick, and RS Erickson. "Effectiveness of a jet injection system in administering morphine and heparin to healthy adults." American Journal of Critical Care 5, no. 1 (1996): 42–48. http://dx.doi.org/10.4037/ajcc1996.5.1.42.

Full text
Abstract:
BACKGROUND: Jet injection eliminates the risk of contaminated needlestick injuries when giving intramuscular or subcutaneous medications. Clinical efficacy of the Biojector System was equivalent to that of needle and syringe injection in unpublished trials with vaccines, but had not been studied using other drugs. OBJECTIVE: To compare the effectiveness of the Biojector with conventional needle and syringe injection in administering intramuscular morphine and subcutaneous heparin to healthy adults, as measured by plasma drug concentration. METHODS: Intramuscular injections of morphine 8 mg (5
APA, Harvard, Vancouver, ISO, and other styles
2

Hadley, SA, M. Chang, and K. Rogers. "Effect of syringe size on bruising following subcutaneous heparin injection." American Journal of Critical Care 5, no. 4 (1996): 271–76. http://dx.doi.org/10.4037/ajcc1996.5.4.271.

Full text
Abstract:
BACKGROUND: Bruising and induration associated with subcutaneous heparin injection often result in sustained tenderness and severe ecchymosis at the injection site. Research-based practice guidelines for subcutaneous heparin administration are needed to reduce these adverse effects. OBJECTIVES: The purpose of this study was to investigate the effect of syringe size (1-mL vs 3-mL) on postinjection-site bruising and induration following the administration of subcutaneous heparin. METHODS: A convenience sample of 29 subjects receiving 5000 units of subcutaneous heparin at least twice a day was re
APA, Harvard, Vancouver, ISO, and other styles
3

Morrison, F. S. "Site for subcutaneous heparin injection." Archives of Internal Medicine 152, no. 1 (1992): 202a—202. http://dx.doi.org/10.1001/archinte.152.1.202a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Inwood, M. J. "Site for subcutaneous heparin injection." Archives of Internal Medicine 153, no. 2 (1993): 263. http://dx.doi.org/10.1001/archinte.153.2.263.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Morrison, Francis S. "Site for Subcutaneous Heparin Injection." Archives of Internal Medicine 152, no. 1 (1992): 202. http://dx.doi.org/10.1001/archinte.1992.00400130192027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Inwood, Martin J. "Site for Subcutaneous Heparin Injection." Archives of Internal Medicine 153, no. 2 (1993): 263. http://dx.doi.org/10.1001/archinte.1993.00410020105014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mar, Adrian W.-Y., Barry Dixon, Kamal Ibrahim, and John D. Parkin. "Skin necrosis following subcutaneous heparin injection." Australasian Journal of Dermatology 36, no. 4 (1995): 201–3. http://dx.doi.org/10.1111/j.1440-0960.1995.tb00974.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tsapatsaris, Nicholas P. "Site for Subcutaneous Heparin Injection-Reply." Archives of Internal Medicine 152, no. 1 (1992): 202. http://dx.doi.org/10.1001/archinte.1992.00400130192028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tsapatsaris, Nicholas P. "Site for Subcutaneous Heparin Injection-Reply." Archives of Internal Medicine 153, no. 2 (1993): 263. http://dx.doi.org/10.1001/archinte.1993.00410020105015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tonn, Michael E., Robyn A. Schaiff, and Marin H. Kollef. "Enoxaparin-Associated Dermal Necrosis: A Consequence of Cross-Reactivity with Heparin-Mediated Antibodies." Annals of Pharmacotherapy 31, no. 3 (1997): 323–26. http://dx.doi.org/10.1177/106002809703100310.

Full text
Abstract:
Objective To describe a patient with enoxaparin-induced dermal necrosis and to review previously reported cases of skin manifestations associated with low-molecular-weight heparins. Case Summary A 43-year-old white woman with adult respiratory distress syndrome developed localized dermal necrosis and thrombocytopenia secondary to subcutaneous administration of unfractionated heparin. Upper extremity thrombi that had developed after administration of subcutaneous heparin at an outside hospital were treated with subcutaneous enoxaparin. Although platelet counts remained stable during enoxaparin
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Subcutaneous heparin injection"

1

Chan, Harriet S. C. "Duration of subcutaneous heparin injections : effect on bruising and pain." Thesis, Curtin University, 2000. http://hdl.handle.net/20.500.11937/460.

Full text
Abstract:
Injection site-pain and bruising are common side effects of subcutaneous heparin injections. These adverse outcomes are problematic for both the patient and the nurse. Specifically, site-pain causes the patient discomfort and bruising limits possible sites for subsequent injections. It is important that nurses use an injection technique that minimises the incidence of adverse outcomes when administering subcutaneous heparin injections. This study examines the effect of duration of subcutaneous heparin injection on site-pain intensity and bruise size experienced by a group of patients being tre
APA, Harvard, Vancouver, ISO, and other styles
2

Chan, Harriet S. C. "Duration of subcutaneous heparin injections : effect on bruising and pain." Curtin University of Technology, School of Nursing, 2000. http://espace.library.curtin.edu.au:80/R/?func=dbin-jump-full&object_id=9868.

Full text
Abstract:
Injection site-pain and bruising are common side effects of subcutaneous heparin injections. These adverse outcomes are problematic for both the patient and the nurse. Specifically, site-pain causes the patient discomfort and bruising limits possible sites for subsequent injections. It is important that nurses use an injection technique that minimises the incidence of adverse outcomes when administering subcutaneous heparin injections. This study examines the effect of duration of subcutaneous heparin injection on site-pain intensity and bruise size experienced by a group of patients being tre
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Subcutaneous heparin injection"

1

Keeling, David. "Therapeutic anticoagulation." In Oxford Textbook of Medicine. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780199204854.003.161602_update_002.

Full text
Abstract:
Low molecular weight heparins (LMWH) have largely replaced unfractionated heparin. Their much more predictable anticoagulant response combined with high bioavailability after subcutaneous injection means that the dose can be calculated by body weight and given subcutaneously without any monitoring or dose adjustment. Their widespread use resulted in most patients with deep vein thrombosis being managed as outpatients, and this is also increasingly the case for uncomplicated pulmonary embolism....
APA, Harvard, Vancouver, ISO, and other styles
2

Keeling, David. "Therapeutic anticoagulation." In Oxford Textbook of Medicine, edited by Jeremy Dwight. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0376.

Full text
Abstract:
The main indications for therapeutic anticoagulation are venous thromboembolism, deep vein thrombosis, and pulmonary embolism, and the prevention of stroke in patients with atrial fibrillation or mechanical heart valves. Low-molecular-weight heparins have largely replaced unfractionated heparin in its treatment. Their much more predictable anticoagulant response combined with high bioavailability after subcutaneous injection means that the dose can be calculated by body weight and given subcutaneously without any monitoring or dose adjustment. Their widespread use resulted in most patients with deep vein thrombosis being managed as outpatients, and this is also increasingly the case for uncomplicated pulmonary embolism. Oral direct inhibitors of anticoagulation that specifically target thrombin or factor Xa are increasingly used to treat acute venous thromboembolism and for stroke prevention in atrial fibrillation.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Subcutaneous heparin injection"

1

Hara, T., M. Iwamoto, H. Ogawa, and M. Tamikawa. "PROPHYLACTIC EFFECT OF ARGIPIDINE (MD-805) ON DEVELOPMENT OF LESIONS IN RAT PERIPHERAL ARTERIAL OCCLUSION MODEL." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644802.

Full text
Abstract:
Argipidine ((2R,4R)-4-methyl-1-(N2-[(RS)-3-methyl-l,2,3,4-tetrahydroquinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylie acid hydrate) is a potent and specific inhibitor of thrombin(Ki=0.039μM). We tested the effect of argipidine on a new animal model of peripheral arterial occlusion (PA0).PA0 was prepared by injection of 5% lactic acid into rat femoral artery. Macroscopic changes of legs progressed asfollows; change to violet color around whole paw (3-24hr), edema (3-24hr), gangrene of fingers (after 24hr) and mummification of whole paw (after 7 days). Pathological examination demonstrated pa
APA, Harvard, Vancouver, ISO, and other styles
2

Johnston, R. V., M. Orr, A. Rumley, J. McLachalan, and C. D. Forbes. "A STUDY OF THE ANTI-THROMBOTIC POTENTIAL OF LOW MOLECULAR WEIGHT HEPARIN LHN-1 (NOVO) IN NORMAL VOLUNTEERS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643225.

Full text
Abstract:
Studies of low molecular weight heparin have shown a molecular sized dependency of the anti-coagulant activity. We studied the effects of a low molecular weight heparin LHN-1 (Novo) with a mean molecular weight of 5-7000 daltons on the coagulation mechanism and platelet function of normal volunteers. The heparin was given for 5 days on a once daily dose of 2500, 5000 or 7500 anti-Xa units to 3 groups of volunteers and in a twice daily regime of 2500 and 5000 anti-Xa units in 2 further groups of volunteers. After subcutaneous injection LHN-1 produced a significant (p<0.01) increase in anti-X
APA, Harvard, Vancouver, ISO, and other styles
3

LE BALC’H, T., a. LANDAIS, T. BUTEL, D. WEILL, J. C. PASCARIELLO, and A. PLANES. "ENOXAPARINE (LOVENOXR), VERSUS STANDARD HEPARIN IN PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) AFTER TOTAL HIP REPLACEMENT (THR)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643691.

Full text
Abstract:
THR is associated with a high risk of thromboembolic complications. Enoxaparine, LovenoxR, a low-molecular-weight-heparin, and standard heparin were compared in their abilities to prevent DVT in patients undergoing THR. The efficiency and the bleeding risk of each treatment were studied.237 patients, with a non traumatic hip disease, requiringTHR, were included in a multicentric, randomized, double blind trial. Mean age:65.8 years ± 9.2; mean weight :67.3kg ± 1.3.113 patients received standard heparin, 5000 UI/8 hrs, by"subcutaneous (SC) injection. 124 patients received Enoxaparine, 40 mg/24 h
APA, Harvard, Vancouver, ISO, and other styles
4

Boneu, B., G. Houin, M. Rostin, J. L. Montastructure, P. d’Azemar, and B. Bayrou. "INTER-INDIVIDUAL PHARMACOKINETIC VARIATIONS AFTER INTRAVENOUS (IV) AND SUBCUTANEOUS (SC) INJECTION OF CY 216 IN HEALTHY SUBJECTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643235.

Full text
Abstract:
We investigated the pharmacokinetic parameters and their inter individual variations of a low molecular weight heparin (LMWH) derivative (CY 216, Fraxiparine R, Choay). In a cross-over study, 100 anti Xa IC u/kg were injected in 12 healthy volunteers, either by IV or SC route, at one week interval. The pharmacological effects were followed on 12 serial citrated samples for 24h: - anti factor Xa (AXa) activity (chromogenic assay calibrated against CY 216); - APTT and thrombin clotting time prolongation. The main pharmacokinetic parameters (elimination half-life (T|); clearance (cl); distributio
APA, Harvard, Vancouver, ISO, and other styles
5

Arnesen, K. E., G. F. Handeland, U. Abildgaard, P. Gottschalk, G. Stene-Larsen, and D. W. T. Nilsen. "WHAT IS THE OPTIMAL DOSAGE OF LMW HEPARIN IN THE SC TREATMENT OF DEEP VENOUS THROMBOSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643593.

Full text
Abstract:
LMW heparin (LMWH) is better suited for subcutaneous (sc) administration than is UF heparin due to higher bioavailability and slower elimination. Optimal dosage for sc treatment of DVT has not been defined. Our previous study suggested that LMWH should be given in doses according to bodyweight (bw), and that sc injection of 100 anti-Xa U/kg bw/12 hrs might result in therapeutic plasma levels (Holm et al. Haemostasis 16, supl 2,30-37, 1986). This dosage is now being evaluated in an open study including patients with venographically proven DVT. Excluded were patients with pulmonary embolism, thr
APA, Harvard, Vancouver, ISO, and other styles
6

Cornelli, U., J. M. Welena, J. Fareed, X. Huan, and D. Hoppensteadt. "ANTITHROMBOTIC ACTIONS OF A SULFOMUCOPOLYSACCHARIDE MIXTURE (ATERIOD) IN ANIMAL MODELS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644160.

Full text
Abstract:
Ateriod obtained from beef mucosal lining is a sulfomuco-polysaccharide mixture of various glycosaminoglycans which contains derma tans, heparatans and traces of heparin. It has been used in the treatment ofatherosclerosis and related vaso-oclusive disorders. Ateriod is standardized in terms of its lipoprotein lipase activation actions. Ateriod contains signfi-cant in vitro anticoagulant and antiprotease (anti-factor Xa and anti-factor Ila) activities as measured by clot-based and chromr ogenic substrate methods. However, this in vitro activity is 7-10 times lesser than heparin. In order to st
APA, Harvard, Vancouver, ISO, and other styles
7

Briel, R. C., P. C. Hermann, and P. Doller. "LOW MOLECULAR WEIGHT HEPARIN (FRAGMIN) PROPHYLAXIS IN GYNECOLOGIC SURGERY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643223.

Full text
Abstract:
In a prospective, randomized study patients undergoing hysterectomy were treated either by the low molecular weight heparin Fragmin or by the combination of unfractionated sodium heparin + dihydroergotamin (HDHE). The dosage in the Fragmin group was 2× 2500 anti Xa-U on day 1 = day of surgery, from day 2-8: 1× 5000 anti Xa-U, in the HDHE-group from day 1-8: 2× 5000 IU heparin + 0.5 mg DHE. 99 patients were randomly allocated to prophylaxis with Fragmin, 101 to HDHE prophylaxis. 95 and 96 respectively were evaluated, the others excluded for different reasons. The 2 groups were comparable for ge
APA, Harvard, Vancouver, ISO, and other styles
8

Albada, J., K. K. Nieuwenhuis, and J. J. Sixma. "PHARMACOKINETICS OF A LOW MOLECULAR WEIGHT HEPARIN (KABI 2165, FRAGMIN) ATFER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION IN HUMAN VOLUNTEERS AND ITS IN VIVO NEUTRALIZATION BY PROTAMINE SULFATE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642866.

Full text
Abstract:
Pharmacokinetics of a low molecular weight heparin (LMWH) were studied in healthy volunteers. After an intravenous bolus injection of 5000 anti-Xa U in 5 healthy volunteers anti Xa activity disappeared according to the combination of saturable and a linear mechanism, preceded by a rapid initial disappearance. The apparent half-life of the anti Xa activity is about twice as long as that of standard heparin. In another set of experiments 5000 anti Xa U of LMWH were immediately followed by 50 mgr of Protamine Sulphate (PS). The curve of the anti Xa-activity parallelled the original curve at a lev
APA, Harvard, Vancouver, ISO, and other styles
9

Forestier, F., F. Daffos, M. Rainaut, P. Cornu, A. Deschamps, and F. Toulemonde. "MAY LMW (CY 216) BE ADMINISTERED DURING PREGNANCY ?" In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643598.

Full text
Abstract:
One of the main problems related to the use of fractionated heparin during pregnancy concerns its transplacental passage.Previous studies showed LMW heparin fraction CY 216 has no teratogenic effects, and when labelled, does not cross the placental barrier in animal, and does not appear into the milk.We studied the transplacental passage following subcutaneous administration of large dosage (17.500 AXa IC u) in 7 women who where going to have an abortion during the third trimester of gestation because of severe fetal malformation, after informed consent.Blood samples were taken before and 3 h
APA, Harvard, Vancouver, ISO, and other styles
10

LE GAGNEUX, F., A. STEG, and M. LE GUILLOU. "SUBCUTANEOUS ENOXAPARINE (LOVENOXR) VERSUS PLACEBO FOR PREVENTING DEEP VEIN THROMBOSIS (DVT) AFTER TRANSURETHRAL PROSTATECTOMY (TUP)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643212.

Full text
Abstract:
The aim of this study was mainly to evaluate the risk of bleeding, and the efficiency of Enoxaparine, a low-molecular-weight-heparin, in preventing DVT in patients undergoing TUP.89 patients (mean age : 67.5 years + 1.3), undergoing TUP, were included in a randomized, double blind study. Patients with a major risk of thromboembolism were excluded. 44 patients received one daily subcutaneous (SC) injection of 60 mg of Enoxaparine ; 45 patients received placebo. All the patients received the first injection 12 hours before operation.Red cell transfusions requirements were not significantly diffe
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography